IGM Biosciences and Sanofi enter deal with USD 6bn potential

US-based IGM Biosciences has signed a deal with French Sanofi to use the company’s ”super molecule” technology to develop drug candidates within oncology, immunology and inflammation.


In the midst of a greater stock fluctuation for US-based IGM Biosciences, the company has entered a multimillion-dollar deal with French Sanofi, a competitor of Novo Nordisk on the insulin area. In aggregate numbers, the deal could reach over USD 6bn, a joint press release reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs